IL-33 antagonists and uses thereof
The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.
1. A method of treating an inflammatory disease or disorder, or at least one symptom associated with the inflammatory disease or disorder, the method comprising administering, to a patient in need thereof, an interleukin-33 (IL-33) antagonist comprising a first IL-33 binding domain (D1), a second IL-33 binding domain (D2), and a multimerizing domain (M), wherein D1, or D2, or both D1 and D2 are attached to the multimerizing domain (M), wherein D1 comprises an extracellular portion of a human suppression of tumorigenicity (ST2) protein, D2 comprises an extracellular portion of a human interleukin-1 receptor accessory protein (IL-1RAcP), and M comprises an Fc portion of an immunoglobulin, wherein the inflammatory disease or disorder is alleviated, or reduced in severity, duration or frequency of occurrence, or at least one symptom associated with the inflammatory disease or disorder is alleviated, or reduced in severity, duration, or frequency of occurrence.
2. The method of claim 1 , wherein the inflammatory disease or disorder is selected from the group consisting of asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, multiple sclerosis, arthritis, allergic rhinitis, eosinophilic esophagitis and psoriasis.
3. The method of claim 2 , wherein the inflammatory disease or disorder is asthma.
4. The method of claim 3 , wherein the asthma is eosinophilic or non-eosinophilic asthma.
5. The method of claim 2 , wherein the asthma is steroid resistant or steroid sensitive asthma.
6. The method of claim 1 , wherein the inflammatory disease or disorder is atopic dermatitis.
7. The method of claim 1 , wherein the inflammatory disease or disorder is chronic obstructive pulmonary disease (COPD).
8. The method of claim 7 , wherein the chronic obstructive pulmonary disease results from, or is caused in part by cigarette smoke.
9. The method of claim 1 , further comprising administering an effective amount of a second therapeutic agent useful for alleviating the inflammatory disease or disorder, or at least one symptom of the inflammatory disease or disorder, or for diminishing an allergic response to an allergen.
10. The method of claim 9 , wherein the second therapeutic agent is selected from the group consisting of a non-steroidal anti-inflammatory (NSAID), a corticosteroid, a bronchial dilator, an antihistamine, epinephrine, a decongestant, a thymic stromal lymphopoietin (TSLP) antagonist, an IL-13 antagonist, an IL-4 antagonist, an IL-4/IL-13 dual antagonist, an IL-5 antagonist, an IL-6 antagonist, an IL-12/23 antagonist, an IL-22 antagonist, an IL-25 antagonist, an IL-17 antagonist, an IL-31 antagonist, an oral PDE4 inhibitor, another IL-33 antagonist, and an antibody to IL-33.
11. The method of claim 1 , wherein D2 is attached to the N-terminus of D1, and wherein D1 is attached to the N-terminus of M.
12. The method of claim 1 , wherein D1 is attached to the N-terminus of M, and D2 is attached to the C-terminus of M.
13. The method of claim 1 , wherein D2 is attached to the N-terminus of M, and D1 is attached to the C-terminus of M.
14. The method of claim 1 , wherein D1 is attached to the C-terminus of M, and D2 is attached to the C-terminus of D1.
15. The method of claim 1 , wherein D2 is attached to the C-terminus of M, and D1 is attached to the C-terminus of D2.
16. The method of claim 1 , wherein D1 is attached to the N-terminus of D2, and wherein D2 is attached to the N-terminus of M.
17. The method of claim 1 , wherein the IL-33 antagonist binds human interleukin 33 (IL-33) with a binding dissociation equilibrium constant (KD) of less than about 80 pM as measured in a surface plasmon resonance assay at 25° C., and/or a binding dissociation equilibrium constant (KD) of less than about 400 pM as measured in a surface plasmon resonance assay at 37° C.
18. The method of claim 1 , wherein the IL-33 antagonist binds monkey interleukin 33 (IL-33) with a binding dissociation equilibrium constant (KD) of less than about 60 pM as measured in a surface plasmon resonance assay at 25° C., and/or a binding dissociation equilibrium constant (KD) of less than about 200 pM as measured in a surface plasmon resonance assay at 37° C.
19. The method of claim 1 , wherein the IL-33 antagonist binds mouse interleukin 33 (IL-33) with a binding dissociation equilibrium constant (KD) of less than about 110 pM as measured in a surface plasmon resonance assay at 25° C., and/or a binding dissociation equilibrium constant (KD) of less than about 100 pM as measured in a surface plasmon resonance assay at 37° C.
20. The method of claim 1 , wherein the IL-33 antagonist binds human interleukin 33 (IL-33) with a dissociative half-life (t½) of greater than or equal to about 9 minutes as measured in a surface plasmon resonance assay at 25° C., and/or a dissociative half-life (t½) of greater than or equal to about 4 minutes as measured in a surface plasmon resonance assay at 37° C.
21. The method of claim 1 , wherein the IL-33 antagonist binds monkey interleukin 33 (IL-33) with a dissociative half-life (t½) of greater than about 40 minutes as measured in a surface plasmon resonance assay at 25° C., and/or a dissociative half-life (t½) of greater than or equal to about 10 minutes as measured in a surface plasmon resonance assay at 37° C.
22. The method of claim 1 , wherein the IL-33 antagonist binds mouse interleukin 33 (IL-33) with a dissociative half-life (t½) of greater than about 25 minutes as measured in a surface plasmon resonance assay at 25° C., and/or a dissociative half-life (t½) of greater than about 30 minutes as measured in a surface plasmon resonance assay at 37° C.
23. The method of claim 1 , wherein the IL-33 antagonist blocks the interaction of IL-33 and ST2.
24. The method of claim 23 , wherein the IL-33 antagonist blocks the interaction of IL-33 and ST2 with an IC50 value of less than about 115 pM as measured in an in vitro receptor/ligand binding assay at 25° C.
25. The method of claim 1 , wherein D1 comprises the amino acid sequence of SEQ ID NO: 5, or an amino acid sequence having at least 90% identity thereto.
26. The method of claim 1 , wherein D2 comprises the amino acid sequence of SEQ ID NO: 7, or an amino acid sequence having at least 90% identity thereto.
27. The method of claim 1 , wherein the immunoglobulin is human IgG.
28. The method of claim 27 , wherein the immunoglobulin is human IgG1.
29. The method of claim 1 , wherein the immunoglobulin is murine IgG.
30. The method of claim 27 , wherein the immunoglobulin is murine IgG2a.
31. The method of claim 1 , wherein the IL-33 antagonist comprises the amino acid sequence of SEQ ID NO: 1.
32. The method of claim 1 , wherein the IL-33 antagonist comprises the amino acid sequence of SEQ ID NO: 2.
33. The method of claim 1 , wherein the IL-33 antagonist comprises the amino acid sequence of SEQ ID NO: 3.
34. The method of claim 1 , wherein the IL-33 antagonist comprises the amino acid sequence of SEQ ID NO: 13.
35. A method of treating an inflammatory disease or disorder, or at least one symptom associated with the inflammatory disease or disorder, the method comprising administering, to a patient in need thereof, an interleukin-33 (IL-33) antagonist comprising a first IL-33 binding domain (D1), a second IL-33 binding domain (D2), and a multimerizing domain (M), wherein D1, or D2, or both D1 and D2 are attached to the multimerizing domain (M), wherein D1 comprises an extracellular portion of a suppression of tumorigenicity (ST2) protein, D2 comprises an extracellular portion of an interleukin-1 receptor accessory protein (IL-1RAcP), and M comprises an Fc portion of an immunoglobulin, wherein the inflammatory disease or disorder is alleviated, or reduced in severity, duration or frequency of occurrence, or at least one symptom associated with the inflammatory disease or disorder is alleviated, or reduced in severity, duration, or frequency of occurrence.
36. A method for treating a patient who demonstrates a sensitivity to an allergen, the method comprising administering, to a patient in need thereof, an interleukin-33 (IL-33) antagonist comprising a first IL-33 binding domain (D1), a second IL-33 binding domain (D2), and a multimerizing domain (M), wherein D1, or D2, or both D1 and D2 are attached to the multimerizing domain (M), wherein D1 comprises an extracellular portion of a human suppression of tumorigenicity (ST2) protein, D2 comprises an extracellular portion of a human interleukin-1 receptor accessory protein (IL-1RAcP), and M comprises an Fc portion of an immunoglobulin, wherein the patient demonstrates a reduced sensitivity to, or a diminished allergic reaction against the allergen, or does not experience any sensitivity or allergic reaction to, or anaphylactic response to the allergen following administration of the IL-33 antagonist.